Journal
JOURNAL OF INORGANIC BIOCHEMISTRY
Volume 106, Issue 1, Pages 90-99Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jinorgbio.2011.09.030
Keywords
Platinum; Ruthenium; Tumour; Therapy; Drug; Mechanism of action
Funding
- SIGEA srl
Ask authors/readers for more resources
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with some success the clinical evaluations of phase I and preliminary phase II trials in patients. Here we highlight the strategies that have led to the discovery of metal-based (NAMI-A and KP1019) and of organometallic (RM175, RAPTA-T, RDC11 and DW1/2) ruthenium-based complexes, and we report their main biological/pharmacological characteristics and expectations for further development. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available